Day: August 12, 2024

Presented data showing 100% disease control rate after 24-week treatment with (Z)-Endoxifen in 40mg cohort of Phase 2 EVANGELINE study at the American Association for Cancer Research (AACR) Annual MeetingCompleted enrollment in 80mg PK Run-in Cohort for EVANGELINE trialCompleted Phase 2 Karisma-Endoxifen clinical trial dosingUpdated protocol for (Z)-Endoxifen and abemaciclib clinical trialEnded second quarter 2024 with $79.5 million in cash and cash equivalents and no debtSEATTLE, Aug. 12, 2024 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced financial results for the fiscal quarter ended June 30, 2024, and provided an update on recent company developments. Atossa is a clinical-stage biopharmaceutical company developing proprietary innovative medicines in areas...

Enrollment commenced in the ACESOT-1051 Phase 1 trial evaluating APR-1051 – no myelosuppression observed in the first of eight planned cohorts at sub-therapeutic dose $28.7 million in cash and cash equivalents as of June 30, 2024 with cash runway extended into Q4 2025 DOYLESTOWN, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financial results for the second quarter ended June 30, 2024, and provided a business update. “Aprea continues to make excellent progress advancing its clinical pipeline of therapeutic candidates,” said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. “We initiated enrollment in the ACESOT-1051 trial, advancing a second...

Driven by robust demand for the Company’s defense and AI-powered solutions, gross revenues for the six-month period ended June 30, 2024, increased by approximately 630%-720% compared to the same six-month period in 2023. The Company expects to publish its financial statements for the six–month period ended June 30, 2024 on August 28, 2024. Rehovot, Israel, Aug. 12, 2024 (GLOBE NEWSWIRE) — Maris-Tech Ltd. (Nasdaq: MTEK, MTEKW) (“Maris-Tech” or the “Company”), a global leader in video and artificial intelligence (AI) based Edge Computing technology, today announced its preliminary gross revenues for the six-month period ended June 30, 2024.The Company expects that its revenues for the six-month period ended June 30, 2024 will be approximately $3,00,000-$3,400,000, which if achieved would reflect...

Significant progress addressing CMC items noted in CRL BLA resubmission remains on track for 2H 2024 CLEVELAND, Aug. 12, 2024 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the second quarter of 2024 and recent corporate progress. “Having completed data generation for nearly all of the Chemistry Manufacturing and Controls deliverables outlined in the Complete Response Letter that we received in April 2024, we are on track to resubmit our Biologics License Application for pz-cel this year and, if approved, bring a treatment option to patients with recessive dystrophic epidermolysis bullosa,” said Vish Seshadri, Chief Executive Officer of Abeona. Second Quarter and Recent Progress Pz-cel for RDEBOn August 8, 2024, Abeona completed a Type A meeting with the U.S. Food and Drug Administration...

Stabilizes business with a return to positive Adjusted EBITDA Promotes Gordon Bean to Chief Financial Officer Announces August 19th conference call to discuss financial resultsSHIRLEY, N.Y., Aug. 12, 2024 (GLOBE NEWSWIRE) — Evome Medical Technologies Inc. ‎(the “Company” or “Evome”) (TSXV: EVMT) today reported financial results for the second quarter ended June 30, 2024, featuring $421,000 in positive Adjusted EBITDA1, a reduction in debt, financial performance momentum and significant progress with its restructuring. The Company’s financial statements for the three and six months ended June 30, 2024 and 2023 and related Management’s Discussion and Analysis (MD&A) are available under the Company’s profile on SEDAR+ (www.sedarplus.com). Financial highlights of Q2 2024 included the following:Revenue of...

Presented cohort one (low dose) data from both trials of TSHA-102 at 2024 IRSF Rett Syndrome Scientific Meeting that demonstrated durable improvements across consistent clinical domains and an encouraging safety profile in adult (up to 52 weeks) and pediatric (up to 22 weeks) patients TSHA-102 was generally well tolerated with no SAEs or DLTs as of initial six-week assessment in first patient in cohort two (high dose) of adolescent/adult trial; IDMC approved dosing of second (adolescent/adult trial) and first (pediatric trial) patient in cohort two, which is scheduled for Q3 2024   Cohort two (n=3) and cohort one (n=2) data from both trials (adolescent/adult and pediatric) expected in 1H 2025 $76.8 million net proceeds from June 2024 public follow-on offering extends anticipated cash runway into Q4 2026    Conference call and live webcast...